Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › CA › Sacramento › NPI 1710918545
Hospital

Regents of the University of California

Regents of the University of California was paid $177.55M by Medicaid between Jan 2018 and Dec 2024, across 628 billing codes. Its largest line is 0450, Emergency room services — 14% of everything it billed.

33Billing provider infoREGENTS OF THE UNIVERSITY OF CALIFORNIA
SACRAMENTO, CA 95817
33aNPI1710918545assigned 07/06/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$177.55M
24GClaims2,705,327
24DCodes billed628
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in California

Rank by total paid#5 of 410
Median peer was paid$6.90M
This provider vs. median26×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official TROVATTEN, TAMMY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$2.0M$4.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018279,710$18.64M
2019321,471$17.44M
2020316,393$17.56M
2021409,472$24.61M
2022433,216$30.09M
2023490,457$37.18M
2024incomplete454,608$32.02M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
0450 Emergency room services 14% 108,272 92,579 $24.25M
74177 Computed tomography, abdomen and pelvis; with contrast material 3.8% 17,260 16,618 $6.80M
J9271 Injection, pembrolizumab, 1 mg 3.3% 669 538 $5.89M
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 2.8% 22,600 19,517 $4.93M
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B 2.7% 26,102 24,565 $4.82M
99202 Office or other outpatient visit for the evaluation and management of a new patient, straightforward 2.7% 60,513 46,781 $4.78M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 2.5% 2,004 1,879 $4.44M
0121 2.4% 635 511 $4.33M
99199 Unlisted special service, procedure or report 2.4% 65,644 49,054 $4.23M
70450 Computed tomography, head or brain; without contrast material 2.1% 13,006 12,496 $3.78M
77386 2.0% 7,086 660 $3.63M
G0463 Hospital outpatient clinic visit for assessment and management of a patient 1.8% 68,026 58,328 $3.27M
616 more codes
99284 Emergency room visit (serious) 1.7% 2,267 $3.02M
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance 1.7% 33,446 $2.98M
72125 Computed tomography, cervical spine; without contrast material 1.6% 6,262 $2.91M
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 1.5% 18,027 $2.67M
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 1.4% 56,837 $2.40M
99201 1.3% 30,592 $2.39M
80053 Comprehensive metabolic panel 1.3% 105,981 $2.38M
71260 Computed tomography, thorax, diagnostic; with contrast material 1.3% 6,954 $2.36M
96375 Therapeutic injection; each additional sequential IV push 1.3% 32,717 $2.36M
96361 Intravenous infusion, hydration; each additional hour 1.3% 27,186 $2.34M
Z7500 1.2% 63,606 $2.14M
J0585 Injection, onabotulinumtoxina, 1 unit 1.1% 1,983 $1.98M
70553 Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences 1.1% 3,627 $1.89M
90791 Psychiatric diagnostic evaluation 1.0% 9,362 $1.85M
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour 1.0% 7,984 $1.84M
J3490 Unclassified drugs <1% 92,536 $1.76M
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 151,260 $1.66M
J1561 Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg <1% 1,537 $1.44M
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 5,682 $1.42M
78815 Positron emission tomography (PET) for limited area imaging <1% 1,061 $1.40M
0510 <1% 32,653 $1.33M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 13,539 $1.26M
71046 Radiologic examination, chest; 2 views <1% 25,268 $1.15M
99499 <1% 12,352 $1.14M
J1745 Injection, infliximab, excludes biosimilar, 10 mg <1% 550 $1.13M
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 11,408 $1.06M
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 30,863 $1.06M
80048 Basic metabolic panel (calcium, ionized) <1% 60,106 $925K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance <1% 12,662 $910K
J9299 Injection, nivolumab, 1 mg <1% 111 $901K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 10,538 $895K
70551 Magnetic resonance imaging, brain; without contrast material <1% 2,165 $875K
71045 Radiologic examination, chest; single view <1% 19,361 $868K
C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 27,323 $811K
70486 <1% 2,555 $804K
86803 <1% 30,508 $785K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 14,484 $771K
71275 Computed tomographic angiography, chest, with contrast material <1% 2,129 $728K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 17,514 $691K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 19,761 $670K
93325 <1% 4,719 $666K
73564 <1% 6,633 $642K
83690 <1% 42,853 $627K
70498 <1% 1,171 $586K
J7050 Infusion, normal saline solution, 250 cc <1% 19,903 $566K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 5,601 $538K
93303 Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study <1% 2,461 $532K
Q5104 Injection, infliximab-abda, biosimilar, (renflexis), 10 mg <1% 471 $521K
0762 <1% 1,438 $520K
0761 <1% 8,947 $508K
72148 Magnetic resonance imaging, lumbar spine; without contrast material <1% 1,307 $475K
0760 <1% 75,033 $466K
82248 <1% 51,568 $465K
Z7502 <1% 12,270 $463K
72141 <1% 1,015 $454K
84484 <1% 25,685 $453K
73610 <1% 7,195 $452K
93970 <1% 1,957 $450K
J2350 Injection, ocrelizumab, 1 mg <1% 26 $449K
P9016 Red blood cells, leukocytes reduced, each unit <1% 934 $443K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 2,190 $427K
70496 <1% 1,094 $427K
76825 <1% 1,186 $412K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 2,052 $411K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 8,300 $406K
73110 <1% 6,640 $399K
73080 <1% 5,094 $380K
83880 <1% 11,738 $376K
82805 <1% 6,585 $366K
99282 Emergency department visit for the evaluation and management, low to moderate severity <1% 859 $361K
73630 <1% 7,584 $359K
73130 <1% 6,806 $357K
73030 <1% 5,033 $342K
73590 <1% 6,149 $341K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 3,749 $335K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 8,316 $328K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 13,950 $325K
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries <1% 1,229 $307K
76770 <1% 3,195 $307K
88185 <1% 603 $307K
93971 <1% 2,210 $307K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 9,632 $305K
J0131 Injection, acetaminophen, not otherwise specified,10 mg <1% 5,537 $298K
0360 <1% 1,913 $295K
0270 <1% 2,424 $276K
86850 <1% 23,590 $276K
84443 Thyroid stimulating hormone (TSH) <1% 15,472 $270K
93975 <1% 954 $269K
73090 <1% 5,016 $262K
70491 <1% 1,029 $261K
70487 <1% 763 $259K
0370 <1% 411 $258K
76830 Ultrasound, transvaginal <1% 2,475 $255K
93320 <1% 2,618 $250K
0160 <1% 3,916 $248K
86900 <1% 24,380 $241K
88341 <1% 1,327 $237K
J0185 Injection, aprepitant, 1 mg <1% 1,402 $236K
0710 <1% 2,647 $230K
96415 <1% 4,000 $228K
Z7506 <1% 1,750 $227K
83735 <1% 28,539 $225K
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 5,409 $222K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 1,914 $221K
85027 <1% 23,801 $219K
76816 Ultrasound, pregnant uterus, real time with image documentation, follow-up <1% 3,366 $215K
73700 <1% 723 $202K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 25,296 $200K
96367 <1% 3,602 $196K
Q4051 Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) <1% 65 $195K
76815 Ultrasound, pregnant uterus, real time with image documentation, limited <1% 2,953 $194K
73060 <1% 2,787 $190K
J0897 Injection, denosumab, 1 mg <1% 203 $189K
90715 <1% 4,187 $188K
J3380 Injection, vedolizumab, intravenous, 1 mg <1% 56 $184K
87086 Culture, bacterial; quantitative colony count, urine <1% 15,607 $181K
84702 <1% 2,797 $181K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 7,060 $176K
G0378 Hospital observation service, per hour <1% 2,627 $175K
73502 <1% 3,072 $169K
83605 <1% 9,390 $168K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 8,240 $167K
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple <1% 1,609 $166K
77336 <1% 2,597 $164K
77334 <1% 564 $158K
74018 <1% 3,663 $156K
76700 Ultrasound, abdominal, real time with image documentation; complete <1% 1,753 $153K
71250 <1% 832 $153K
J0485 Injection, belatacept, 1 mg <1% 239 $150K
72156 <1% 239 $146K
81001 <1% 23,712 $146K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 2,795 $144K
74183 <1% 631 $144K
Q5107 Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg <1% 101 $139K
0301 <1% 786 $137K
82803 <1% 4,271 $135K
86901 <1% 24,542 $131K
87522 Neg quan hep c or qual rna <1% 2,068 $131K
72100 <1% 2,685 $128K
82962 <1% 22,885 $128K
76801 <1% 1,476 $127K
83036 Hemoglobin; glycosylated (A1C) <1% 15,169 $127K
76827 <1% 1,176 $124K
J1170 Injection, hydromorphone, up to 4 mg <1% 10,535 $124K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 16,587 $123K
0636 <1% 613 $123K
J1815 Injection, insulin, per 5 units <1% 2,780 $122K
73552 <1% 3,481 $120K
72082 <1% 1,989 $118K
86923 <1% 1,487 $116K
77301 <1% 98 $114K
J0178 Injection, aflibercept, 1 mg <1% 62 $113K
96417 <1% 2,275 $111K
86140 <1% 14,057 $111K
76870 <1% 1,139 $110K
87040 <1% 5,331 $109K
0460 <1% 1,835 $109K
Z9725 <1% 2,475 $106K
94010 <1% 2,880 $105K
J2704 Injection, propofol, 10 mg <1% 9,025 $104K
81025 <1% 13,344 $101K
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 2,251 $100K
85610 <1% 20,790 $99K
77300 <1% 362 $98K
85730 <1% 8,437 $96K
86780 <1% 7,683 $95K
94618 <1% 1,103 $92K
72070 <1% 996 $91K
96409 <1% 2,763 $90K
72040 <1% 1,521 $90K
95782 <1% 78 $86K
92504 <1% 2,826 $86K
A9579 Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml <1% 4,258 $83K
0250 <1% 1,381 $83K
76536 <1% 1,472 $82K
0700 <1% 1,265 $82K
92557 <1% 1,193 $82K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 1,271 $80K
86003 <1% 730 $80K
84100 <1% 16,064 $78K
74174 <1% 241 $76K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 15,157 $75K
87077 <1% 6,089 $75K
86922 <1% 1,011 $75K
J2270 Injection, morphine sulfate, up to 10 mg <1% 5,422 $74K
87799 <1% 1,608 $74K
88342 <1% 2,422 $74K
J3475 Injection, magnesium sulfate, per 500 mg <1% 4,954 $73K
76857 <1% 1,096 $73K
83970 <1% 2,363 $72K
76811 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed <1% 592 $71K
85652 <1% 11,546 $71K
J8499 Prescription drug, oral, non chemotherapeutic, nos <1% 8,906 $71K
J7120 Ringers lactate infusion, up to 1000 cc <1% 5,717 $70K
Z7514 <1% 1,245 $70K
J0780 Injection, prochlorperazine, up to 10 mg <1% 2,989 $70K
81003 <1% 16,915 $69K
72197 <1% 275 $69K
85379 <1% 3,778 $67K
84439 <1% 7,128 $61K
72157 <1% 109 $61K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 118 $60K
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 12,248 $60K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 2,465 $60K
73721 Magnetic resonance imaging, any joint of lower extremity; without contrast material <1% 278 $59K
J0875 Injection, dalbavancin, 5 mg <1% 13 $59K
87186 <1% 4,300 $59K
87631 <1% 657 $58K
95816 <1% 618 $58K
86480 <1% 1,453 $55K
95004 Percutaneous tests with allergenic extracts, immediate type reaction <1% 97 $54K
36415 Collection of venous blood by venipuncture <1% 7,747 $53K
J3370 Injection, vancomycin hcl, 500 mg <1% 1,890 $52K
97750 <1% 1,049 $52K
45380 Colonoscopy, flexible; with biopsy, single or multiple <1% 599 $52K
72158 <1% 68 $52K
96411 <1% 673 $51K
82784 <1% 3,878 $49K
72146 <1% 121 $49K
72131 <1% 158 $49K
87493 <1% 1,172 $48K
77295 <1% 40 $48K
Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg <1% 26 $47K
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 7,951 $47K
72170 <1% 871 $47K
93226 <1% 731 $47K
76512 <1% 709 $47K
80197 <1% 3,960 $46K
J3590 Unclassified biologics <1% 331 $46K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 7,344 $46K
87081 <1% 4,100 $46K
A4649 Surgical supply; miscellaneous <1% 1,078 $46K
Z7512 <1% 1,774 $45K
80061 Lipid panel <1% 6,073 $44K
96523 <1% 1,382 $44K
99070 <1% 1,374 $44K
83516 <1% 2,702 $43K
87340 <1% 3,325 $41K
81002 <1% 10,369 $39K
72050 <1% 760 $37K
87070 <1% 3,020 $37K
82728 <1% 4,621 $36K
88184 <1% 572 $36K
Z7508 <1% 617 $36K
80076 <1% 2,985 $36K
92567 <1% 921 $36K
A4217 Sterile water/saline, 500 ml <1% 2,216 $35K
76820 <1% 374 $35K
J9267 Injection, paclitaxel, 1 mg <1% 217 $34K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion <1% 2,459 $34K
94726 <1% 795 $34K
77290 <1% 132 $34K
82140 <1% 1,656 $33K
86235 <1% 627 $32K
82550 <1% 3,821 $32K
59025 Fetal non-stress test <1% 2,377 $32K
81514 <1% 109 $31K
82570 <1% 8,332 $31K
80164 <1% 1,317 $31K
84466 <1% 3,554 $31K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 354 $31K
J2777 Injection, faricimab-svoa, 0.1 mg <1% 12 $30K
96368 <1% 1,030 $30K
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 529 $30K
J1650 Injection, enoxaparin sodium, 10 mg <1% 1,896 $30K
93356 <1% 808 $29K
J0690 Injection, cefazolin sodium, 500 mg <1% 3,355 $29K
93017 <1% 349 $29K
94729 <1% 821 $28K
77338 <1% 105 $28K
92582 <1% 341 $28K
72110 <1% 465 $28K
70544 <1% 139 $28K
87497 <1% 597 $27K
93922 <1% 628 $27K
96416 <1% 586 $26K
J1644 Injection, heparin sodium, per 1000 units <1% 2,774 $26K
73000 <1% 473 $26K
0306 <1% 545 $25K
J7030 Infusion, normal saline solution , 1000 cc <1% 3,524 $25K
J0134 Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg <1% 473 $25K
77067 Screening mammography, bilateral, including computer-aided detection <1% 968 $24K
76942 <1% 367 $24K
93225 <1% 497 $24K
J2060 Injection, lorazepam, 2 mg <1% 2,888 $23K
0305 <1% 692 $23K
95886 <1% 466 $23K
42820 Tonsillectomy and adenoidectomy; younger than age 12 <1% 124 $23K
73562 <1% 926 $23K
92014 Ophthalmological services: medical examination and evaluation, comprehensive, established patient <1% 564 $23K
88108 <1% 1,288 $23K
87653 <1% 907 $21K
J1953 Injection, levetiracetam, 10 mg <1% 298 $21K
Z5924 <1% 295 $21K
88313 <1% 885 $21K
92552 <1% 1,065 $20K
J1756 Injection, iron sucrose, 1 mg <1% 256 $20K
73560 <1% 1,027 $20K
86706 <1% 2,052 $20K
83540 <1% 4,197 $20K
J7060 5% dextrose/water (500 ml = 1 unit) <1% 3,787 $19K
95810 Polysomnography; sleep staging with 4 or more additional parameters <1% 65 $19K
L8699 Prosthetic implant, not otherwise specified <1% 13 $19K
82330 <1% 790 $19K
93296 <1% 1,061 $19K
84156 <1% 6,806 $18K
73600 <1% 696 $18K
94060 <1% 381 $18K
92134 <1% 3,001 $18K
96450 <1% 65 $18K
90686 <1% 2,952 $18K
J9190 Injection, fluorouracil, 500 mg <1% 1,044 $18K
92060 <1% 1,244 $17K
87205 <1% 2,873 $17K
82378 <1% 1,217 $17K
0750 <1% 191 $17K
86704 <1% 1,618 $17K
83615 <1% 2,972 $16K
95819 <1% 207 $16K
X4301 <1% 170 $16K
86038 <1% 1,384 $16K
J2785 Injection, regadenoson, 0.1 mg <1% 124 $16K
J0561 Injection, penicillin g benzathine, 100,000 units <1% 32 $16K
84703 <1% 325 $16K
92579 <1% 286 $15K
69436 Tympanostomy (requiring insertion of ventilating tube), general anesthesia <1% 102 $15K
76000 <1% 357 $15K
82746 <1% 1,306 $15K
J9045 Injection, carboplatin, 50 mg <1% 460 $14K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 526 $14K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 529 $14K
85007 <1% 3,588 $14K
P9040 Red blood cells, leukocytes reduced, irradiated, each unit <1% 32 $14K
92650 <1% 43 $14K
73140 <1% 451 $14K
86360 <1% 369 $14K
J0475 Injection, baclofen, 10 mg <1% 13 $13K
86160 <1% 757 $13K
76642 <1% 305 $13K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 891 $12K
A4216 Sterile water, saline and/or dextrose, diluent/flush, 10 ml <1% 1,679 $12K
J1790 Injection, droperidol, up to 5 mg <1% 566 $12K
92555 <1% 502 $12K
77387 <1% 51 $12K
85045 <1% 2,631 $12K
59841 <1% 37 $11K
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg <1% 1,128 $11K
J1630 Injection, haloperidol, up to 5 mg <1% 1,460 $11K
72190 <1% 267 $11K
87507 <1% 31 $11K
J1642 Injection, heparin sodium, (heparin lock flush), per 10 units <1% 3,774 $11K
86359 <1% 371 $11K
82607 <1% 1,515 $11K
0300 <1% 660 $11K
90670 <1% 214 $11K
96401 <1% 535 $10K
Z7510 <1% 176 $10K
70543 <1% 40 $10K
82533 <1% 682 $10K
84403 <1% 726 $10K
J3360 Injection, diazepam, up to 5 mg <1% 266 $10K
74178 <1% 54 $9K
88307 <1% 251 $9K
83520 <1% 615 $9K
96379 <1% 256 $9K
82785 <1% 558 $9K
J9370 Vincristine sulfate, 1 mg <1% 1,036 $9K
J1940 Injection, furosemide, up to 20 mg <1% 883 $9K
88304 <1% 608 $8K
86225 <1% 705 $8K
92012 Ophthalmological services: medical examination and evaluation, intermediate, established patient <1% 147 $8K
Z7610 <1% 2,139 $8K
82105 <1% 563 $8K
J7999 Compounded drug, not otherwise classified <1% 202 $8K
88173 <1% 382 $8K
90682 <1% 334 $8K
86364 <1% 641 $8K
87075 <1% 592 $8K
76937 <1% 250 $7K
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r <1% 120 $7K
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 1,328 $7K
86304 <1% 584 $7K
88142 <1% 1,366 $7K
73701 <1% 12 $7K
72128 <1% 12 $7K
76805 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation <1% 60 $7K
J0171 Injection, adrenalin, epinephrine, 0.1 mg <1% 131 $7K
84481 <1% 538 $7K
89051 <1% 1,203 $7K
92133 <1% 513 $7K
90677 <1% 100 $7K
99354 <1% 60 $7K
86147 <1% 100 $7K
76882 <1% 362 $7K
87486 <1% 86 $6K
87581 <1% 86 $6K
J0689 Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg <1% 328 $6K
80069 <1% 1,256 $6K
0260 <1% 82 $6K
84165 <1% 728 $6K
77080 <1% 265 $6K
82977 <1% 704 $6K
71020 <1% 285 $6K
82397 <1% 314 $5K
82565 <1% 1,830 $5K
S0164 Injection, pantoprazole sodium, 40 mg <1% 281 $5K
P9047 Infusion, albumin (human), 25%, 50 ml <1% 49 $5K
67028 Intravitreal injection of a pharmacologic agent <1% 122 $5K
97165 <1% 77 $5K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 738 $5K
J3371 Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg <1% 74 $5K
S0020 Injection, bupivicaine hydrochloride, 30 ml <1% 1,148 $5K
96402 <1% 494 $5K
86787 <1% 561 $5K
87536 <1% 104 $5K
84153 <1% 424 $5K
73200 <1% 25 $5K
J0640 Injection, leucovorin calcium, per 50 mg <1% 120 $5K
73070 <1% 159 $5K
96900 <1% 501 $5K
86146 <1% 84 $5K
86800 <1% 415 $4K
82043 <1% 1,540 $4K
77063 Screening digital breast tomosynthesis, bilateral <1% 814 $4K
92550 <1% 165 $4K
94375 <1% 91 $4K
91322 <1% 73 $4K
J2919 Injection, methylprednisolone sodium succinate, 5 mg <1% 260 $4K
73100 <1% 155 $4K
83883 <1% 309 $4K
73521 <1% 142 $4K
86255 <1% 213 $4K
45385 Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) <1% 40 $4K
86790 <1% 404 $4K
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 508 $4K
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg <1% 145 $3K
77001 <1% 54 $3K
85384 <1% 343 $3K
70250 <1% 52 $3K
J1610 Injection, glucagon hydrochloride, per 1 mg <1% 15 $3K
X4540 <1% 96 $3K
83020 <1% 267 $3K
86592 <1% 580 $3K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 289 $3K
88360 <1% 145 $3K
86431 <1% 423 $3K
92526 <1% 89 $3K
J2997 Injection, alteplase recombinant, 1 mg <1% 12 $3K
J0571 Buprenorphine, oral, 1 mg <1% 380 $3K
82010 <1% 266 $3K
J2560 Injection, phenobarbital sodium, up to 120 mg <1% 27 $3K
92553 <1% 82 $3K
Z5916 <1% 56 $3K
J1171 Injection, hydromorphone, 0.1 mg <1% 171 $3K
83021 <1% 151 $3K
0730 <1% 232 $3K
84550 <1% 786 $3K
J2003 Injection, lidocaine hydrochloride, 1 mg <1% 139 $3K
87517 <1% 193 $3K
84425 <1% 450 $3K
87102 <1% 326 $3K
C9113 Injection, pantoprazole sodium, per vial <1% 167 $3K
86665 <1% 63 $3K
85651 <1% 495 $3K
95885 <1% 65 $2K
86301 <1% 157 $2K
82610 <1% 224 $2K
86258 <1% 226 $2K
97162 <1% 25 $2K
51741 <1% 103 $2K
86644 <1% 177 $2K
J2175 Injection, meperidine hydrochloride, per 100 mg <1% 172 $2K
83001 <1% 172 $2K
96156 <1% 25 $2K
91200 <1% 152 $2K
86376 <1% 180 $2K
0272 <1% 116 $2K
82525 <1% 332 $2K
72195 <1% 12 $2K
82670 <1% 115 $2K
93880 <1% 12 $2K
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg <1% 879 $2K
92083 <1% 90 $2K
86334 <1% 160 $2K
82747 <1% 148 $2K
00000 <1% 57 $2K
74021 <1% 27 $2K
83525 <1% 209 $2K
J9217 Leuprolide acetate (for depot suspension), 7.5 mg <1% 12 $2K
84590 <1% 320 $2K
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg <1% 82 $2K
84450 <1% 534 $2K
77073 <1% 51 $2K
80178 <1% 115 $1K
76514 <1% 254 $1K
93978 <1% 13 $1K
J7042 5% dextrose/normal saline (500 ml = 1 unit) <1% 120 $1K
83993 <1% 114 $1K
85613 <1% 132 $1K
84630 <1% 359 $1K
36561 <1% 12 $1K
74220 <1% 40 $1K
73501 <1% 40 $1K
86762 <1% 183 $1K
77065 Tomosynthesis, mammo <1% 25 $1K
90656 <1% 151 $1K
86200 <1% 176 $1K
84155 <1% 587 $1K
J0295 Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm <1% 93 $1K
92507 Treatment of speech, language, voice, communication, and/or auditory processing disorder <1% 85 $1K
90480 <1% 77 $1K
Q3014 Telehealth originating site facility fee <1% 136 $1K
85240 <1% 78 $1K
97161 <1% 129 $1K
0324 <1% 255 $1K
83002 <1% 94 $1K
86664 <1% 63 $1K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 20 $1K
85246 <1% 39 $1K
87529 <1% 17 $1K
Q0111 Wet mounts, including preparations of vaginal, cervical or skin specimens <1% 419 $996.30
71010 <1% 63 $990.19
83051 <1% 96 $986.86
96376 <1% 16 $975.29
S0077 Injection, clindamycin phosphate, 300 mg <1% 69 $972.32
86663 <1% 63 $953.60
0420 <1% 605 $945.03
J1611 Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg <1% 12 $922.24
Z5918 <1% 38 $824.60
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 21 $790.33
Z4311 <1% 65 $783.25
73010 <1% 25 $783.13
82950 <1% 312 $775.99
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 82 $737.81
84146 <1% 91 $737.44
77066 Tomosynthesis, mammo <1% 34 $731.84
95874 <1% 85 $711.58
0115U <1% 13 $689.72
Z4302 <1% 26 $626.60
82310 <1% 184 $621.94
92025 <1% 112 $600.12
0424 <1% 73 $596.65
0302 <1% 69 $586.64
95983 <1% 12 $579.08
J9263 Injection, oxaliplatin, 0.5 mg <1% 26 $575.28
0307 <1% 288 $570.85
84134 <1% 57 $564.14
90662 <1% 216 $560.82
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) <1% 24 $555.36
87206 <1% 103 $537.16
82040 <1% 232 $521.32
J2470 Injection, pantoprazole sodium, 40 mg <1% 60 $502.55
93297 <1% 208 $478.37
88312 <1% 45 $458.92
J2550 Injection, promethazine hcl, up to 50 mg <1% 86 $455.72
64615 <1% 40 $439.28
74000 <1% 19 $416.08
G0008 Administration of influenza virus vaccine <1% 304 $415.90
84305 <1% 65 $411.47
93298 <1% 44 $407.69
J7613 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg <1% 194 $393.58
85576 <1% 14 $390.78
85245 <1% 13 $373.49
80299 <1% 27 $367.07
88300 <1% 83 $366.72
86341 <1% 12 $362.77
97010 <1% 321 $351.41
Q0112 All potassium hydroxide (koh) preparations <1% 148 $348.85
87116 <1% 14 $336.04
86593 <1% 66 $321.31
96150 <1% 12 $303.05
86355 <1% 14 $301.44
87210 <1% 149 $297.39
83527 <1% 36 $291.74
82180 <1% 27 $291.04
94664 <1% 15 $276.21
Z5920 <1% 12 $260.40
97139 <1% 444 $256.35
82085 <1% 47 $253.50
J9000 Injection, doxorubicin hydrochloride, 10 mg <1% 34 $239.70
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 30 $238.63
0320 <1% 42 $232.17
84132 <1% 61 $199.08
73565 <1% 12 $196.80
86709 <1% 12 $162.58
82627 <1% 12 $162.52
J1836 Injection, metronidazole, 10 mg <1% 25 $148.27
H1003 Prenatal care, at-risk enhanced service; education <1% 13 $145.36
82150 <1% 25 $142.12
51705 <1% 39 $128.50
87015 <1% 14 $128.03
0124A <1% 12 $120.00
92250 <1% 24 $119.45
G0279 Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) <1% 15 $110.53
80177 <1% 14 $108.00
84446 <1% 15 $105.00
82103 <1% 12 $101.90
84295 <1% 29 $99.01
90744 <1% 17 $98.73
83721 <1% 12 $94.91
G1003 Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program <1% 538 $94.49
87324 <1% 14 $90.50
82435 <1% 25 $90.06
82272 <1% 16 $89.83
83930 <1% 14 $83.18
T1999 Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" <1% 22 $63.13
J9260 Injection, methotrexate sodium, 50 mg <1% 73 $56.33
0402 <1% 24 $52.24
84207 <1% 14 $35.00
90732 <1% 13 $34.50
99459 <1% 13 $30.42
88311 <1% 13 $29.71
0352 0% 91 $0.00
0258 0% 152 $0.00
51798 0% 28 $0.00
97810 0% 64 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTROVATTEN, TAMMY (VICE PRESIDENT, GOV'T REIMBURSEMENT)
Same official

Other billing entities under TROVATTEN, TAMMY

Full network →
ProviderLocationPaid
Regents of the Univ of CaSacramento, CA$7.35M
Regents of the University of CaSacramento, CA$5.03M
Regents of the Univ of CaSacramento, CA$3.55M
Regents of the University of CaSacramento, CA$2.55M
Regents of the University of CaSacramento, CA$2.35M
Regents of the University of CaSacramento, CA$2.07M
Regents of the Univ of CaSacramento, CA$2.05M
Regents of the Univ of CaSacramento, CA$1.86M
Regents of the University of CaSacramento, CA$1.60M
Regents of the Univ of CaSacramento, CA$1.57M
Regents of the Univ of CaSacramento, CA$1.47M
Regents of the University of CaSacramento, CA$1.31M
Regents of the University of CaSacramento, CA$1.25M
Regents of the Univ of CaSacramento, CA$895K
Regents of the Univ of CaSacramento, CA$861K
Regents of the Univ of CaSacramento, CA$851K
Regents of the Univ of CaSacramento, CA$738K
Regents of the Univ of CaSacramento, CA$665K
Regents of the Univ of CaSacramento, CA$632K
Regents of the Univ of CaSacramento, CA$456K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.